A prospective observational study on the long-term results of 90Yttrium citrate radiosynoviorthesis of synovitis in osteoarthritis of the knee joint

Margit Szentesi, Zoltán Nagy, P. Géher, István Papp, Willm Uwe Kampen

Research output: Contribution to journalArticle

Abstract

Objectives: Radiosynoviorthesis (RSO) is used for the treatment of inflammatory joint diseases. However, there are no long-term results published comparing it to conservative therapy. Therefore, the aim of this prospective observational study was to evaluate response rates after radionuclide therapy in patients suffering from knee osteoarthritis over a time period of 10 years. Methods: Radionuclide therapy with intra-articular administration of colloidal 90Yttrium citrate was performed in osteoarthritic patients [Kellgren–Lawrence grades I/II (n = 69) and Kellgren–Lawrence grade III (n = 72)]. Results: In patients with early-stage disease, an excellent/good response with respect to pain, joint mobility, and function was observed in 82.5% for 1 year and in 73.7% for 8 years after therapy. Responses declined to 50% at 10 years post treatment. In grade III patients, an excellent/good response was observed in 45.9%; a decline to 41.2% was observed in the first 8 years. In this group, the number of patients available for follow-up after 9 and 10 years dropped significantly from 51 patients after 8 years to only 30 patients after 9 years, and to nine patients after 10 years. As a result, these response rates were not appraisable. Conclusion: Long-term results of radiosynoviorthesis in knee osteoarthritis are excellent/good in many patients. The response rate depends on Kellgren–Lawrence stages, and early-stage radionuclide therapy for osteoarthritis is suggested.

Original languageEnglish
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Synovitis
Knee Osteoarthritis
Knee Joint
Citric Acid
Observational Studies
Prospective Studies
Radioisotopes
Therapeutics
Joint Diseases
Arthralgia
Osteoarthritis
Joints

Keywords

  • Yttrium citrate
  • Intra-articular radionuclide therapy
  • Osteoarthritis
  • Radiosynoviorthesis

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

@article{72c75127b01d4dd8831a317bffa5fa19,
title = "A prospective observational study on the long-term results of 90Yttrium citrate radiosynoviorthesis of synovitis in osteoarthritis of the knee joint",
abstract = "Objectives: Radiosynoviorthesis (RSO) is used for the treatment of inflammatory joint diseases. However, there are no long-term results published comparing it to conservative therapy. Therefore, the aim of this prospective observational study was to evaluate response rates after radionuclide therapy in patients suffering from knee osteoarthritis over a time period of 10 years. Methods: Radionuclide therapy with intra-articular administration of colloidal 90Yttrium citrate was performed in osteoarthritic patients [Kellgren–Lawrence grades I/II (n = 69) and Kellgren–Lawrence grade III (n = 72)]. Results: In patients with early-stage disease, an excellent/good response with respect to pain, joint mobility, and function was observed in 82.5{\%} for 1 year and in 73.7{\%} for 8 years after therapy. Responses declined to 50{\%} at 10 years post treatment. In grade III patients, an excellent/good response was observed in 45.9{\%}; a decline to 41.2{\%} was observed in the first 8 years. In this group, the number of patients available for follow-up after 9 and 10 years dropped significantly from 51 patients after 8 years to only 30 patients after 9 years, and to nine patients after 10 years. As a result, these response rates were not appraisable. Conclusion: Long-term results of radiosynoviorthesis in knee osteoarthritis are excellent/good in many patients. The response rate depends on Kellgren–Lawrence stages, and early-stage radionuclide therapy for osteoarthritis is suggested.",
keywords = "Yttrium citrate, Intra-articular radionuclide therapy, Osteoarthritis, Radiosynoviorthesis",
author = "Margit Szentesi and Zolt{\'a}n Nagy and P. G{\'e}her and Istv{\'a}n Papp and Kampen, {Willm Uwe}",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s00259-019-04350-3",
language = "English",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - A prospective observational study on the long-term results of 90Yttrium citrate radiosynoviorthesis of synovitis in osteoarthritis of the knee joint

AU - Szentesi, Margit

AU - Nagy, Zoltán

AU - Géher, P.

AU - Papp, István

AU - Kampen, Willm Uwe

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objectives: Radiosynoviorthesis (RSO) is used for the treatment of inflammatory joint diseases. However, there are no long-term results published comparing it to conservative therapy. Therefore, the aim of this prospective observational study was to evaluate response rates after radionuclide therapy in patients suffering from knee osteoarthritis over a time period of 10 years. Methods: Radionuclide therapy with intra-articular administration of colloidal 90Yttrium citrate was performed in osteoarthritic patients [Kellgren–Lawrence grades I/II (n = 69) and Kellgren–Lawrence grade III (n = 72)]. Results: In patients with early-stage disease, an excellent/good response with respect to pain, joint mobility, and function was observed in 82.5% for 1 year and in 73.7% for 8 years after therapy. Responses declined to 50% at 10 years post treatment. In grade III patients, an excellent/good response was observed in 45.9%; a decline to 41.2% was observed in the first 8 years. In this group, the number of patients available for follow-up after 9 and 10 years dropped significantly from 51 patients after 8 years to only 30 patients after 9 years, and to nine patients after 10 years. As a result, these response rates were not appraisable. Conclusion: Long-term results of radiosynoviorthesis in knee osteoarthritis are excellent/good in many patients. The response rate depends on Kellgren–Lawrence stages, and early-stage radionuclide therapy for osteoarthritis is suggested.

AB - Objectives: Radiosynoviorthesis (RSO) is used for the treatment of inflammatory joint diseases. However, there are no long-term results published comparing it to conservative therapy. Therefore, the aim of this prospective observational study was to evaluate response rates after radionuclide therapy in patients suffering from knee osteoarthritis over a time period of 10 years. Methods: Radionuclide therapy with intra-articular administration of colloidal 90Yttrium citrate was performed in osteoarthritic patients [Kellgren–Lawrence grades I/II (n = 69) and Kellgren–Lawrence grade III (n = 72)]. Results: In patients with early-stage disease, an excellent/good response with respect to pain, joint mobility, and function was observed in 82.5% for 1 year and in 73.7% for 8 years after therapy. Responses declined to 50% at 10 years post treatment. In grade III patients, an excellent/good response was observed in 45.9%; a decline to 41.2% was observed in the first 8 years. In this group, the number of patients available for follow-up after 9 and 10 years dropped significantly from 51 patients after 8 years to only 30 patients after 9 years, and to nine patients after 10 years. As a result, these response rates were not appraisable. Conclusion: Long-term results of radiosynoviorthesis in knee osteoarthritis are excellent/good in many patients. The response rate depends on Kellgren–Lawrence stages, and early-stage radionuclide therapy for osteoarthritis is suggested.

KW - Yttrium citrate

KW - Intra-articular radionuclide therapy

KW - Osteoarthritis

KW - Radiosynoviorthesis

UR - http://www.scopus.com/inward/record.url?scp=85066311041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066311041&partnerID=8YFLogxK

U2 - 10.1007/s00259-019-04350-3

DO - 10.1007/s00259-019-04350-3

M3 - Article

AN - SCOPUS:85066311041

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

ER -